Wenzhi Li
- Cancer Research top 10%
- Cancer-related molecular mechanisms research 13
- MicroRNA in disease regulation 5
- Cancer, Lipids, and Metabolism 2
-
- Sirtuins and Resveratrol in Medicine 2
-
- Endometrial and Cervical Cancer Treatments 2
-
- Circular RNAs in diseases 6
- RNA modifications and cancer 4
- RNA Research and Splicing 4
- Co-authors
- Jie JiangZhiming LiuChunping QiuQing ZhouShuhong GaoXiaohong MaYun ZouXingming Jiang
- Partner nations
- ChinaUnited StatesDenmark
In The Last Decade
Wenzhi Li
26 papers receiving 490 citations
Peers
Comparison fields: 5 of 76
- Cancer Research 274
- Geriatrics and Gerontology 20
- Obstetrics and Gynecology 39
- Reproductive Medicine 40
- Molecular Biology 300
Countries citing papers authored by Wenzhi Li
This map shows the geographic impact of Wenzhi Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wenzhi Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wenzhi Li more than expected).
Fields of papers citing papers by Wenzhi Li
This network shows the impact of papers produced by Wenzhi Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wenzhi Li. The network helps show where Wenzhi Li may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Wenzhi Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2023 | 7 | |
| 3 | 2021 | 9 | |
| 4 | 2021 | 38 | |
| 5 | 2021 | 7 | |
| 6 | 2020 | 18 | |
| 7 | 2020 | 19 | |
| 8 | 2020 | 15 | |
| 9 | Long non-coding RNA SNHG5 affects the invasion and apoptosis of renal cell carcinoma by regulating the miR-363-3p-Twist1 interaction. | 2020 | 17 |
| 10 | 2019 | 16 | |
| 11 | 2019 | 33 | |
| 12 | 2019 | 14 | |
| 13 | 2018 | 30 | |
| 14 | 2018 | 47 | |
| 15 | 2018 | 32 | |
| 16 | 2018 | 31 | |
| 17 | 2018 | 17 | |
| 18 | 2016 | 1 | |
| 19 | Effectiveness of inhibitor rapamycin, saracatinib, linsitinib and JNJ-38877605 against human prostate cancer cells. | 2015 | 6 |
| 20 | 2014 | 13 |
About Wenzhi Li
Wenzhi Li is a scholar working on Cancer Research, Geriatrics and Gerontology and Biochemistry, having authored 27 papers that have together received 492 indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (13 papers), Circular RNAs in diseases (6 papers), MicroRNA in disease regulation (5 papers), RNA modifications and cancer (4 papers), RNA Research and Splicing (4 papers), Sirtuins and Resveratrol in Medicine (2 papers), Endometrial and Cervical Cancer Treatments (2 papers) and Cancer, Lipids, and Metabolism (2 papers). The work is most often cited by research in Cancer Research (274 citations), Geriatrics and Gerontology (20 citations) and Obstetrics and Gynecology (39 citations). Wenzhi Li has collaborated with scholars based in China, United States and Denmark. Frequent co-authors include Jie Jiang, Zhiming Liu, Chunping Qiu, Qing Zhou, Shuhong Gao, Xiaohong Ma, Yun Zou, Xingming Jiang, Yanfei Feng and Xin Li. Their work appears in journals such as Life Sciences, BMC Dermatology, Molecular Oncology, Oncology Reports and Cell Death and Disease.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.